Morgan Stanley Downgrades Compass to Equal-Weight, Lowers Price Target to $5

Morgan Stanley analyst Brian Nowak downgrades Compass (NYSE:COMP) from Overweight to Equal-Weight and lowers the price target from $7 to $5.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Morgan Stanley analyst Brian Nowak downgrades Compass (NYSE:COMP) from Overweight to Equal-Weight and lowers the price target from $7 to $5.

Luby’s To Sell Cafeteria Restaurant Business For $28.7M

By Shivani Kumaresan

Today, 4:32 AM

Luby’s Inc (NYSE:LUB) inked an agreement to sell its cafeteria restaurant business to a newly formed affiliate of Calvin Gin. The…

LUB

News

Surna Cultivation Technologies Partners With Evoqua Water Technologies To Offer Water Treatment Solutions

By Benzinga Newsdesk

Today, 4:32 AM

Surna Cultivation Technologies LLC, a leader in controlled environment agriculture (CEA) systems engineering and technologies, and a subsidiary of CEA Industries Inc. (NASDAQ:CEAD), is proud to announce another

CEAD

JP Morgan Downgrades Meritage Homes to Neutral, Lowers Price Target to $111

By Benzinga Newsdesk

Today, 4:32 AM

JP Morgan analyst Michael Rehaut downgrades Meritage Homes (NYSE:MTH) from Overweight to Neutral and lowers the price target from $148 to $111.

MTH

Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds

By Madhukumar Warrier

Today, 4:32 AM

Regeneron Pharmaceutical Inc.’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail reduced the risk of death by 20% in hospitalized COVID-19 patients who have not mounted their own antibody response, a large-scale study in the U.K. published on Wednesday found.

REGN

Morgan Stanley Downgrades Compass to Equal-Weight, Lowers Price Target to $5

Related Posts

Luby’s To Sell Cafeteria Restaurant Business For $28.7M

Surna Cultivation Technologies Partners With Evoqua Water Technologies To Offer Water Treatment Solutions

JP Morgan Downgrades Meritage Homes to Neutral, Lowers Price Target to $111

Regeneron Antibody Treatment Cuts Risk Of Death In Some Critical COVID-19 Patients, Large-Scale Study Finds